An effect of the combination of oncolytic adenoviruses and a tyrosine-kinase inhibitor.

2017 Fiscal Year Final Research Report

• Project/Area Number: 16K21639
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Respiratory organ internal medicine; Biological pharmacy
• Research Institution: Chiba Cancer Center (Research Institute)
• Principal Investigator: Morinaga Takao 千葉県がんセンター(研究所), がん治療開発グループ, 研究員 (30757000)
• Project Period (FY): 2016-04-01 – 2018-03-31
• Keywords: 悪性中皮腫 / 遺伝子治療 / アデノウイルス / チロシンキナーゼ / 細胞周期

Outline of Final Research Achievements

Malignant mesothelioma is an intractable disease; thereby, development of innovative new drugs, which has a non-traditional strategy for cancer treatment is required. We focused on effectiveness of oncolytic adenoviruses on mesothelioma and further explored a drug that can strengthen the antitumor effect of the viruses. Our results suggested that a Wee1 kinase inhibitor could enhance the replication of adenoviruses and augment the cytotoxicity induced by the viruses through the apoptotic pathway.

Free Research Field

分子腫瘍生物学